Skip to main content
. 2015 Mar 31;75(6):1135–1141. doi: 10.1007/s00280-015-2730-y

Table 3.

Treatment-related grade 1–2 and grade 3–4 adverse events

Total [n (%)]
No. of patients N = 31 (100)
CTC grade Grade 1–2 Grade 3–4
Adverse event
Mucositisa 18 (58) 1 (3)
Fatigue 17 (55)
Hand-foot syndrome 9 (29) 5 (16)
Diarrhea 13 (42) 2 (6)
Nausea 16 (52)
Skinb 20 (65) 1 (3)
Anorexia 8 (26)
Vomiting 12 (39) 1 (3)
Neuropathy 7 (23)
Constipation 4 (13)
Ankle edema 5 (16)
Epistaxis 4 (13)
Infection 3 (10)
Hematology
Anemia 25 (81) 1 (3)
Thrombocytopenia 14 (45) 2 (6)
Neutropenia 12 (39)
Clinical chemistry
Hyperglycemiac 13 (42) 14 (45)
AP 19 (61) 2 (6)
ASAT 11 (35)
ALAT 12 (39)
Hypokalemia 10 (32) 5 (16)
Hyponatremia 7 (23)
Hypertriglyceridemia 7 (23)
GGT 13 (42) 9 (29)
Bilirubin 4 (13) 1 (3)
Hypercholesteremia 3 (10)

GGT gamma-glutamyltransferase, ASAT aspartate aminotransferase, ALAT alanine aminotransferase, AP alkaline phosphatase

aMucositis including aphthous ulcers and stomatitis

bSkin toxicity includes rash, itching, color and nail changes

cNon-fasting glucose